Besides, a series of studies have found that the number of CD8+ T cells or the ratio of CD8+/CD4+ T cells in the tumor microenvironment are correlated with ICIs outcomes and serve as positive predictors of immunotherapy [46, 47]. This evidence concerns the gene CD8A and neoplasm.